Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
or

Synthetic Biologics Inc (SYN)

Synthetic Biologics Inc (SYN)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
1.0200 +0.0100 (+0.99%) 10/12/22 [NYSE Arca]
N/A x N/A N/A x N/A
Post-market 1.0200 unch (unch) -
Quote Overview for Wed, Oct 12th, 2022
Day Low
0.9700
Day High
1.0200
Open 1.0200
Previous Close 1.0100 1.0100
Volume 57,700 57,700
Avg Vol 49,125 49,125
Stochastic %K 22.33% 22.33%
Weighted Alpha -82.00 -82.00
5-Day Change -0.1300 (-11.30%) -0.1300 (-11.30%)
52-Week Range 0.9700 - 4.5600 0.9700 - 4.5600
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 16,161
  • Shares Outstanding, K 15,844
  • Annual Sales, $ 0 K
  • Annual Income, $ -14,270 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 1.38
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.26
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.01
  • Most Recent Earnings $-0.31 on 08/11/22
  • Next Earnings Date 11/02/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -1.05
  • Growth Rate Est. (year over year) +95,242.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9700 +5.15%
on 10/12/22
Period Open: 1.4200
1.4700 -30.61%
on 09/13/22
-0.4000 (-28.17%)
since 09/12/22
3-Month
0.9700 +5.15%
on 10/12/22
Period Open: 2.3760
2.3990 -57.48%
on 07/13/22
-1.3560 (-57.07%)
since 07/12/22
52-Week
0.9700 +5.15%
on 10/12/22
Period Open: 4.4300
4.5600 -77.63%
on 10/14/21
-3.4100 (-76.98%)
since 10/12/21

Most Recent Stories

More News
Synthetic Biologics Reports Second Quarter 2022 Operational Highlights and Financial Results

-Prioritizing the advancement of novel oncolytic adenovirus (OV) platform- -Cash balance as of August 1, 2022 of $53.5 million, including the additional...

SYN : 1.0200 (+0.99%)
Synthetic Biologics to Host Conference Call and Webcast to Discuss Second Quarter 2022 Operational Highlights and Financial Results

ROCKVILLE, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing...

SYN : 1.0200 (+0.99%)
Synthetic Biologics Announces $3 Million Private Placement of Convertible Preferred Stock

ROCKVILLE, Md., July 29, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc.. (NYSE American: SYN) (“Synthetic Biologics” or the “Company”), a diversified...

SYN : 1.0200 (+0.99%)
Synthetic Biologics Announces Reverse Stock Split

ROCKVILLE, Md., July 15, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing...

SYN : 1.0200 (+0.99%)
Synthetic Biologics Reports First Quarter 2022 Operational Highlights and Financial Results

-Encouraging data further supports the development of novel oncolytic adenovirus (OV) platform; Announced a peer-reviewed publication highlighting positive...

SYN : 1.0200 (+0.99%)
Synthetic Biologics Announces Formation of Scientific Advisory Board to Advance Oncology Pipeline

Scientific Advisory Board of leading experts in oncolytic adenoviruses and gene therapies strengthens transformative clinical development strategy and...

SYN : 1.0200 (+0.99%)
Synthetic Biologics Announces Journal for ImmunoTherapy of Cancer Publication of Phase 1 Trial of Intravenous VCN-01 Oncolytic Adenovirus in Patients With Advanced Solid Tumors

-Data support VCN-01 acceptable safety profile with encouraging biological and clinical activity, and identify recommended Phase 2 dose (RP2D)- ...

SYN : 1.0200 (+0.99%)
Synthetic Biologics to Participate in the Maxim 2022 Virtual Growth Conference

ROCKVILLE, Md., March 22, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing...

SYN : 1.0200 (+0.99%)
Synthetic Biologics Reports 2021 Year End Operational Highlights and Financial Results

-Completed acquisition of VCN Biosciences, expanding pipeline into oncology- -VCN-01 received Orphan Drug Designation for retinoblastoma from the U.S....

SYN : 1.0200 (+0.99%)
Synthetic Biologics Completes Acquisition of VCN Biosciences

- Expands pipeline into oncology with unique, clinical-stage oncolytic viruses optimized for intravenous administration - - Strong cash position to...

SYN : 1.0200 (+0.99%)

Business Summary

Synthetic Biologics, Inc. is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. The Company is engaged in developing product candidates to treat pulmonary arterial hypertension, relapses in multiple...

See More

Key Turning Points

3rd Resistance Point 1.0867
2nd Resistance Point 1.0533
1st Resistance Point 1.0367
Last Price 1.0200
1st Support Level 0.9867
2nd Support Level 0.9533
3rd Support Level 0.9367

See More

52-Week High 4.5600
Fibonacci 61.8% 3.1886
Fibonacci 50% 2.7650
Fibonacci 38.2% 2.3414
Last Price 1.0200
52-Week Low 0.9700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar